SOUTH SAN FRANCISCO, Calif., June 26, 2024 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (LYEL), a clinical‑stage T-cell reprogramming company advancing a diverse pipeline of cell therapies for ...

Please provide your email address to receive an email when new articles are posted on . Younger patients who received higher doses of tisagenlecleucel for advanced B-cell acute lymphoblastic leukemia ...

Presentations on the first day of the 2023 American Society of Clinical Oncology Annual Meeting covered data on a split dose CAR T-cell therapy and a CAR T therapy manufactured with TKI. Less than a ...